Testing of the integrity of the recurrent laryngeal nerve during thyroid surgery has become routine practice for many surgeons to aid dissection and minimise the chance of inadvertent nerve injury. We hypothesised that routine reversal of an intermediateacting, non-depolarising neuromuscular blocking agent would improve conditions for stimulation of the recurrent laryngeal nerve. We conducted a single-centre, randomised, double-blind placebo-controlled trial of patients undergoing thyroid surgery by the same surgeon. After randomisation, the participants received either neostigmine 2.5 mg with glycopyrrolate 0.4 mg or placebo, at 30 minutes after induction of anaesthesia and administration of 0.4 mg/kg of atracurium. The primary outcome was the subjective assessment by the surgeon as to whether the neuromuscular function was adequate for stimulation of the recurrent laryngeal nerve using a neuromuscular integrity monitor (NIM). Time to NIM stimulation was 44.6 minutes in the placebo group and 41.4 minutes in the intervention group (P=0.268). Of the 21 patients who received the neuromuscular blockade reversal, 20 (95.2%) had adequate surgical conditions for NIM stimulation, compared to 9 out of 18 patients (50%) in the placebo group (P=0.002). Three of the ten patients (30%) with inadequate reversal showed no evidence of residual blockade assessed peripherally. The routine reversal of neuromuscular blockade at 30 minutes post induction appears to result in adequate surgical conditions for safe stimulation of the recurrent laryngeal nerve. Return of neuromuscular function at a peripheral site does not guarantee adequate laryngeal muscle function for use of the NIM.
It has become routine practice to test the integrity of the recurrent laryngeal nerves (RLNs) during thyroid surgery with intraoperative nerve monitoring, to aid RLN dissection and assist prevention of damage to the RLN 1 . Although there is currently no definitive evidence to prove a reduced incidence of recurrent laryngeal nerve injury 2 , this practice has been enthusiastically adopted. For the nerve monitoring to be effective, a specially designed tracheal tube must be positioned in the trachea such that the wires exposed on the surface of the tube contact the vocal cords and complete the electrical circuit when they are stimulated to adduct. The neuromuscular integrity monitor (NIM) tube has a larger external diameter than a standard tracheal tube and is subjectively more difficult to place.
This neuromuscular monitoring technique poses a dilemma for the anaesthetist-should neuromuscular blockade be used or not? If a non-depolarising muscle relaxant is used to place the NIM tracheal tube, it should improve the quality of intubation conditions and reduce trauma to the larynx 3 . This is particularly true given the greater potential for the NIM tracheal tube to cause trauma and sore throat because of its larger size and difficult placement. Suxamethonium may of course be used instead of a non-depolarising agent, however its use is also problematic, with the risk of myalgia and multiple well-recognised complications and contraindications. The final alternative is the avoidance of a muscle relaxant for tracheal tube placement, ensuring confident testing of nerve function but increasing the risk of trauma caused by intubation. Trauma to the airway may complicate the assessment of laryngeal function in the postoperative period, so the practice of many anaesthetists is to use an intermediate-acting non-depolarising agent to produce optimal conditions for intubation. The sensitivity of muscles to paralysing agents differs in onset and duration, due to muscle size, receptor density and bloodflow. The laryngeal muscles appear to be more resistant to neuromuscular blocking agents. Studies using rocuronium and mivacurium have shown a longer time to paralysis after the agent has been administered and shorter duration of action 4, 5 . Consequently, studies using peripheral nerve stimulation may not be able to accurately estimate the degree of blockade of the muscles of the larynx but have been thought to overestimate the degree of block. This study was prompted by the contrary experience using atracurium: peripheral nerve stimulation at either the adductor pollicis or peroneal nerves did not appear to reflect neuromuscular function with simultaneous direct recurrent laryngeal nerve stimulation during thyroid surgery.
Our aim in undertaking this study was a practical one: we wanted to determine if routine neuromuscular blockade reversal given 30 minutes following induction of anaesthesia and administration of atracurium provided adequate conditions for thyroid surgery, defined as adequate recovery from paralysis to allow normal use of the nerve stimulator. Normal use of the nerve stimulator was deemed present if the RLN was confidently identified and the nerve stimulator appropriately stimulated the RLN resulting in a detected electromyogram (EMG). The effects of routine administration of a reversal agent were compared to the alternative strategy of awaiting spontaneous return of neuromuscular function. If it could be shown that routine reversal provides adequate surgical conditions then there should be no barrier to using a moderate dose of non-depolarising relaxant to minimise potential complications related to tracheal intubation. Our secondary aim was to determine if peripheral nerve stimulation reflected the adequacy of laryngeal neuromuscular function following surgical electrical stimulation of the recurrent laryngeal nerve.
Methods
This single-centre, randomised, double-blind clinical trial received approval by the Peninsula Health Ethics Committee (HREC/11/PH/62) and is registered with the ANZ Clinical Trial Registry (ACTRN12611000914965). The Drugs and Therapeutics Committee at Frankston Health granted permission for this study. All surgeries were conducted at Peninsula Health, Frankston Hospital, Victoria, over a continuous 11-month period commencing August 2011.
Patients eligible for inclusion in the study were those undergoing thyroid surgery by a single surgeon, requiring intraoperative neuromuscular monitoring. Recruitment was conducted by either the principal or associate researcher. Informed, written consent was obtained before commencement of surgery. Participants were excluded if there was an allergy to atracurium, musculoskeletal abnormality, risk of gastric aspiration, pre-existing recurrent laryngeal nerve injury or abnormality, minors and those unable to give informed consent.
A random sequence generator was used to randomise the allocation of the participants into intervention (neuromuscular reversal) and placebo (saline) groups by provision of instructions contained in a sealed, opaque envelope.
Anaesthesia was conducted with a standard technique for all participants: anaesthesia was induced with propofol and atracurium 0.4 mg/kg and subsequently maintained with a remifentanil infusion 0.1 μg/kg/min and sevoflurane 1 MAC. Dexamethasone and cephazolin were also routinely administered to minimise swelling and risk of wound infection, respectively. Tracheal intubation was performed using a Medtronic NIM endotracheal tube (Medtronic, Minneapolis, MN, USA), size 6.0 for females and 7.0 for males.
An independent person prepared a 5 ml solution of either 2.5 mg neostigmine with 0.4 mg of glycopyrrolate, if in the reversal group, or 5 ml 0.9% normal saline, if in the placebo group, as determined by the computer-generated randomisation schedule. This was labelled only as "study drug" and administered intravenously 30 minutes after the atracurium by the anaesthetist, who was blinded to its composition.
The surgeon performed recurrent laryngeal nerve stimulation using a Medtronic Neuro 2.0 monitor (Medtronic, Minneapolis, MN, USA), with a current of 1 mA and frequency of 2 Hz. This results in supramaximal stimulation of the motor fibres of the RLN. Vocal cord adduction was recorded by the EMG endotracheal tube and the threshold for sensitivity was set at 100 microvolts. The surgeon was also blinded to the medication given and was asked to determine if there was adequate recovery from paralysis to safely use the nerve stimulator. This subjective assessment of the degree of residual paralysis at the larynx by the surgeon rather than strict EMG criteria was the primary outcome for this study. This clinical determination was made by 1) adduction of the vocal cords evidenced by the EMG trace and 2) palpation of the posterior cricoarytenoid muscle by the surgeon in the post-cricoid space. If complete or incomplete paralysis remained in either group, then a rescue dose of reversal (2.5 mg of neostigmine, 0.4mg of glycopyrrolate) was administered and recorded.
The peripheral train-of-four (TOF) and train-of-four ratio (TOFR) were tested one minute prior to and five, 30, 35, 45 and 60 minutes following the administration of atracurium by the use of an Innervator peripheral nerve stimulator (Fisher & Paykel Healthcare Pty Ltd, Ringwood, Victoria). The stimulation after induction of anaesthesia, but prior to administration of the muscle relaxant, was to ensure a supramaximal stimulus was provided to the common peroneal nerve. This nerve was chosen as it was distant to the surgery and behind a drape and therefore not able to be visualised by the surgeon. These TOF and TOFR data were taken to ensure that an adequate dose of relaxant was given and, later, to ensure that the relaxant effect had worn off. The TOFR was also measured at the time of first recurrent laryngeal nerve stimulation.
The primary outcome measure was the subjective adequacy of the vocal cord response to nerve stimulation at the time of first identification of the RLN during surgery, as determined by the surgeon.
A power calculation to identify a difference of adequate conditions between 50% of patients in the placebo group to 90% of patients in the intervention group showed that 19 patients would be required in each group (Fisher's exact test, α <0.01, 1-β=0.80). This power calculation was informed by a period of observation prior to the commencement of the study. Statistics were analysed using Fisher's exact test for nominal variables and Student's t-tests for scale variables using SPSS version 20 for Macintosh (IBM, Armonk, NY, USA).
Results
Thirty-nine patients were enrolled in the study, with 21 receiving the neuromuscular blockade reversal intervention (Figure 1 ). There were no differences between the demographics of the placebo and intervention groups ( Table 1) .
The time to recurrent laryngeal nerve stimulation was equivalent in both the placebo and intervention groups (Table  2) . However, in the placebo group, half of the participants had inadequate surgical conditions (9 of 18, 50%) compared to only one patient (1 of 21, 4.8%) in the intervention group. A further patient initially thought to have adequate surgical conditions was given rescue reversal in the placebo group at the surgeon's request.
In the patients who did not have adequate surgical conditions, three (30%) showed no evidence of fade on peripheral nerve stimulation by palpation (TOFR=1.0). There were no differences between the duration to nerve stimulation between the patients with inadequate and adequate surgical conditions (42.7 and 42.9 minutes, respectively, P=0.951).
None of the patients were found to have recurrent laryngeal nerve injuries postoperatively at routine follow-up. One patient who had initially consented was excluded from the study due to an anaphylactic reaction to the cephazolin given prior to induction. 
Discussion
Of the 21 participants in the reversal treatment arm, only one participant had inadequate conditions for stimulation with the neuromuscular integrity monitor at the laryngeal nerve. In the placebo group, only half of the participants were found to have conditions adequate for stimulation of the recurrent laryngeal nerve. However, following a dose of rescue neuromuscular blockade reversal, all recovered sufficient neuromuscular junction activity within five minutes to be successfully stimulated by the neuromuscular integrity monitor. This suggests that reversal after 30 minutes of administration of atracurium and prior to neuromuscular integrity monitoring of the recurrent laryngeal nerve appears to be a useful approach to facilitate the monitoring technique.
At the time of recurrent laryngeal nerve stimulation, three participants had no evidence of residual neuromuscular blockade at the peripheral neuromuscular junction. In these cases the inadequate conditions for stimulation of the recurrent laryngeal nerve may demonstrate the differences in the sensitivity of muscles to paralysing agents and thus, spontaneous return of neuromuscular function. This is in contrast to previous studies that have demonstrated a quicker recovery from neuromuscular blockade at the laryngeal muscles compared to peripheral sites such as the adductor pollicis 5, 6 . A comparable study to ours, conducted by Chu et al 7 , found that using rocuronium or atracurium to facilitate intubation did not affect the use of intraoperative neuromuscular integrity monitoring at a time similar to the stimulation in our study. However, Chu et al elicited electromyography responses from the vagus nerve and the physiological variances of the vagus nerve and the recurrent laryngeal branches make it difficult to draw conclusions about the efficacy of stimulation of the recurrent laryngeal nerve. A study by Phelan and colleagues demonstrated significantly different latencies and thresholds between the vagus and recurrent laryngeal nerves 8 . The effect of muscle relaxation on vagal and recurrent laryngeal nerve function was not examined in Phelan et al's study, however they suggest the use of vagal stimulation may be useful in determining if the circuit is functioning correctly.
There is a wide inter-individual variation in the response to non-depolarising neuromuscular blocking drugs, particularly with coexisting disease. Dubois et al 9 examined the spontaneous offset time of atracurium after a dose of 0.5 mg/kg in patients with moderate and severe systemic disease (American Society of Anesthesiologists scores of III and IV) including renal failure (35%), hepatic failure (25%) and both renal and hepatic failure (10%). The mean time to reach a peripheral TOF ratio of 0.75 (T4/T1) of the adductor pollicis was 70.57±8.98 minutes. The time taken for TOF ratio to be 0.75 when using atracurium to facilitate intubation was much longer than the average time to stimulation of the recurrent laryngeal nerve in our study, although this duration could be expected to be longer than in otherwise healthy individuals.
A subjectively normal TOFR at a peripheral site, indicating return of neuromuscular function at the peripheries, did not guarantee sufficient return of neuromuscular function at the level of the vocal cords in our study. To reliably use a NIM tracheal tube for thyroid surgery would therefore require either not using a non-depolarising muscle relaxant at intubation (thus accepting an increase in risk of laryngeal injury), waiting a much longer time until stimulation of the recurrent laryngeal nerve or routinely using a dose of reversal agent. In most hospitals and surgical centres, waiting extra time to allow for spontaneous return of neuromuscular function is not a feasible option because of patient throughput.
Although it is generally accepted that the use of neuromuscular blocking agents does help reduce the incidence of significant morbidity and mortality related to laryngeal injury associated with intubation 3 , a retrospective study by Birkholz et al 10 showed that there was no increase in laryngeal side-effects if a muscle relaxant was omitted. However, the retrospective nature of that study may be criticised for the potential for bias in patient selection for the use of muscle relaxant versus a different anaesthetic technique.
Although other studies have looked at the safe use of neuromuscular blocking agents and the intraoperative stimulation of varying nerves during thyroid surgery, no other study has given a reversal agent routinely prior to stimulation of the recurrent laryngeal nerve. It is routine practice to give neostigmine at the conclusion of surgery to ensure that no residual paralysis remains and to facilitate safe extubation. Changing the timing of this reversal dose, as we did in our study, appears to improve the conditions for stimulation by the surgeon.
The strength of this study comes from the randomisation of patients to prevent selection bias. We believe that using a different approach to the timing of reversal of neuromuscular blockade results in both a safer and easier intubation for the anaesthetist and the best surgical conditions for use of the neuromuscular integrity monitor. The potential benefits are to reduce inadvertent damage to the laryngeal structures and the recurrent laryngeal nerve.
An accelerometer was not available for this study and would have allowed more detailed assessment of the common peroneal TOFR to explore the relationship between the peripheral and laryngeal responses. It has long been assumed that return of neuromuscular function at peripheral nerve sites, as evidenced by a lack of fade at these sites, will correlate to return of function at laryngeal and pharyngeal muscle groups 11, 12 . Given the discrepancies between our observations and previous literature, further investigation into this is warranted.
Future studies may consider the use of sugammadex for reversal of aminosteroid non-depolarising neuromuscular blocking drugs to achieve the same result as obtained here. The current cost of sugammadex may limit its routine use in this setting, particularly as the technique of atracurium and traditional reversal medications described here has proven so successful.
Conclusion
Surgical conditions to allow normal use of the nerve stimulator on the RLN were significantly improved when reversal of neuromuscular blockade was given at 30 minutes after induction of anaesthesia. This technique potentially increases the safety and ease of intubation using a NIM tracheal tube, as there is no barrier for using a non-depolarising muscle relaxant, while still providing optimal conditions for the surgeon, thus reducing the risk of inadvertent recurrent laryngeal nerve injury during thyroid surgery.
